The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.
about
A processed pseudogene codes for a new antigen recognized by a CD8(+) T cell clone on melanoma.Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodiesEscape mutations alter proteasome processing of major histocompatibility complex class I-restricted epitopes in persistent hepatitis C virus infection.The proteasome activator 11 S REG (PA28) and class I antigen presentationThe specificity of proteasomes: impact on MHC class I processing and presentation of antigens.Relationship of p53 overexpression on cancers and recognition by anti-p53 T cell receptor-transduced T cellsTumour immunotherapy: new tools, new treatment modalities and new T-cell antigens.Recognition of fresh human tumor by human peripheral blood lymphocytes transduced with a bicistronic retroviral vector encoding a murine anti-p53 TCR.Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going?INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.Hepatitis C virus mutation affects proteasomal epitope processingInterferon-gamma, the functional plasticity of the ubiquitin-proteasome system, and MHC class I antigen processing.Complementary role of CD4+ T cells and secondary lymphoid tissues for cross-presentation of tumor antigen to CD8+ T cells.Cytotoxic T lymphocyte epitopes of HIV-1 Nef: Generation of multiple definitive major histocompatibility complex class I ligands by proteasomes.Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes.The T210M Substitution in the HLA-a*02:01 gp100 Epitope Strongly Affects Overall Proteasomal Cleavage Site Usage and Antigen Processing.Development of multi-epitope vaccines targeting wild-type sequence p53 peptides.Preventing tumor escape by targeting a post-proteasomal trimming independent epitope.Diversity of escape variant mutations in Simian virus 40 large tumor antigen (SV40 Tag) epitopes selected by cytotoxic T lymphocyte (CTL) clones.Mutation or loss of Wilms' tumor gene 1 (WT1) are not major reasons for immune escape in patients with AML receiving WT1 peptide vaccination.A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates.Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.Frameshift peptide-derived T-cell epitopes: a source of novel tumor-specific antigens.Generation of cytotoxic T cell responses to an HLA-A24 restricted epitope peptide derived from wild-type p53.Cytotoxic T-lymphocyte clones, established by stimulation with the HLA-A2 binding p5365-73 wild type peptide loaded on dendritic cells In vitro, specifically recognize and lyse HLA-A2 tumour cells overexpressing the p53 protein.Effect of epitope flanking residues on the presentation of N-terminal cytotoxic T lymphocyte epitopes.Long-term multiepitopic cytotoxic-T-lymphocyte responses induced in chimpanzees by combinations of Plasmodium falciparum liver-stage peptides and lipopeptides.Prediction of proteasome cleavage motifs by neural networks.Impact of p53-based immunization on primary chemically-induced tumors.Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.A structural model of 20S immunoproteasomes: effect of LMP2 codon 60 polymorphism on expression, activity, intracellular localisation and insight into the regulatory mechanisms.The N-terminal flanking region of the TRP2360-368 melanoma antigen determines proteasome activator PA28 requirement for epitope liberation.
P2860
Q30865419-EFB92D09-8A23-455E-9070-9031FADDFBF3Q33610671-30A61175-5AAB-4CA2-B235-0C37265E6380Q33724145-D4ED7AC9-6104-43BE-A4A3-A005BBAF7029Q33796158-B70B8F4F-2538-4DB1-A277-737B43DE46FEQ33815363-04557665-2780-4E5C-8430-3F83145F8921Q33927506-561D0FAA-45AE-4BA5-A11F-269D02E54100Q34265381-5A622127-0E27-4F2B-964A-2BFBBB358E52Q34657661-3739BD5B-46F6-4D1F-8FB2-F56849DA6176Q34669820-65B316AC-7E72-45E1-9A82-713021384889Q35136043-A1E4A9E9-33FA-45F3-8B0F-40534DDB73A5Q35142669-1BD8B7A4-4C2A-4860-BC38-38596B50F3BFQ35835376-F6C72B6F-1991-4079-ACC6-762D942ADBECQ36266425-85AD4306-1482-42DD-9705-D858F05F2BC1Q36370664-80E73CE8-D480-4E51-B396-158883D773D0Q36375737-F5E80EA0-4AB1-4332-880D-554A3106D4C4Q36375899-9B799119-5B35-4EE1-86CA-935EBEAE2316Q36381923-325647AF-C24C-493B-9D75-528A11AC8E09Q37259621-F907A596-FD19-43B9-8E6B-CE2BFB72774DQ37346707-41852481-F86D-48BD-900B-B541BC54400DQ37400231-5EFED6CA-91E1-4B8D-9D9C-447D60365BDDQ39767227-C3622430-9D71-4A52-938D-345D09414E33Q40169547-91D7ED44-A79A-426E-8547-97DD2EEC08A3Q40777946-4C6F47F3-C10F-41C6-B2E5-948B5C08EA04Q40801080-EBBD6B9E-3125-4ABE-8C43-591B8CE70DEEQ40812116-3385EEC1-494B-448C-9128-E61A9576F6FAQ40903376-377DD407-B223-4B15-A918-E9AFEC76FAE7Q40938559-CF0533EC-287A-47F0-94DD-6CF2BD83196BQ41195668-955CC15C-E06C-4795-B879-C2D54D85269EQ43976304-4E61BC2E-1805-4D8F-AEC6-7C7B8602BE49Q45130509-2378BA25-7975-4727-9400-04032723FE02Q45887190-E93E968D-62F0-4ABC-8803-AA70B636F3D6Q48588098-D25326C2-59F8-4DE7-A40D-D05640E449E7Q52927378-F3011A8B-5BB4-4956-9CB6-D1E18BD2A24F
P2860
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh
1998年學術文章
@zh-hant
name
The sequence alteration associ ...... or a flanking peptide epitope.
@ast
The sequence alteration associ ...... or a flanking peptide epitope.
@en
type
label
The sequence alteration associ ...... or a flanking peptide epitope.
@ast
The sequence alteration associ ...... or a flanking peptide epitope.
@en
prefLabel
The sequence alteration associ ...... or a flanking peptide epitope.
@ast
The sequence alteration associ ...... or a flanking peptide epitope.
@en
P2093
P2860
P356
P1476
The sequence alteration associ ...... or a flanking peptide epitope.
@en
P2093
A Häussler
A J Levine
E A Ferreira
J Hernandez
L A Sherman
M Theobald
P M Kloetzel
P2860
P304
P356
10.1084/JEM.188.6.1017
P407
P577
1998-09-01T00:00:00Z